Denali Therapeutics Statistics
Total Valuation
DNLI has a market cap or net worth of $2.15 billion. The enterprise value is $1.15 billion.
Important Dates
The last earnings date was Tuesday, May 6, 2025, after market close.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DNLI has 145.28 million shares outstanding. The number of shares has increased by 20.87% in one year.
| Current Share Class | 145.28M |
| Shares Outstanding | 145.28M |
| Shares Change (YoY) | +20.87% |
| Shares Change (QoQ) | +0.67% |
| Owned by Insiders (%) | 4.97% |
| Owned by Institutions (%) | 88.58% |
| Float | 130.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 51.21 |
| PB Ratio | 1.91 |
| P/TBV Ratio | 1.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.56, with a Debt / Equity ratio of 0.05.
| Current Ratio | 9.56 |
| Quick Ratio | 8.92 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5,152.06 |
Financial Efficiency
Return on equity (ROE) is -35.21% and return on invested capital (ROIC) is -24.03%.
| Return on Equity (ROE) | -35.21% |
| Return on Assets (ROA) | -22.58% |
| Return on Invested Capital (ROIC) | -24.03% |
| Return on Capital Employed (ROCE) | -43.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.08M |
| Employee Count | 422 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DNLI has paid $68,000 in taxes.
| Income Tax | 68,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.17% in the last 52 weeks. The beta is 1.49, so DNLI's price volatility has been higher than the market average.
| Beta (5Y) | 1.49 |
| 52-Week Price Change | -19.17% |
| 50-Day Moving Average | 14.45 |
| 200-Day Moving Average | 22.01 |
| Relative Strength Index (RSI) | 50.10 |
| Average Volume (20 Days) | 1,425,120 |
Short Selling Information
The latest short interest is 11.74 million, so 8.08% of the outstanding shares have been sold short.
| Short Interest | 11.74M |
| Short Previous Month | 13.00M |
| Short % of Shares Out | 8.08% |
| Short % of Float | 8.97% |
| Short Ratio (days to cover) | 8.29 |
Income Statement
| Revenue | n/a |
| Gross Profit | -395.24M |
| Operating Income | -515.21M |
| Pretax Income | -419.62M |
| Net Income | -453.94M |
| EBITDA | -513.95M |
| EBIT | -515.21M |
| Earnings Per Share (EPS) | -$2.67 |
Full Income StatementBalance Sheet
The company has $817.93 million in cash and $51.57 million in debt, giving a net cash position of $1.00 billion or $6.90 per share.
| Cash & Cash Equivalents | 817.93M |
| Total Debt | 51.57M |
| Net Cash | 1.00B |
| Net Cash Per Share | $6.90 |
| Equity (Book Value) | 1.12B |
| Book Value Per Share | 7.73 |
| Working Capital | 786.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$365.54 million and capital expenditures -$18.84 million, giving a free cash flow of -$384.38 million.
| Operating Cash Flow | -365.54M |
| Capital Expenditures | -18.84M |
| Free Cash Flow | -384.38M |
| FCF Per Share | -$2.65 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |